Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062 | 0.98 | CYP1A2 (0.46) | CYP1A2HRH3ALDH1A1KCNH2CHRM5 | |
| SCHEMBL8587237 | 0.84 | CYP1A2 (0.50) | CYP1A2HRH3ALDH1A1CHRM5ADRA2C | |
| SCHEMBL3951154 | 0.83 | DRD2 (0.37) | CYP1A2ALDH1A1KDM4EDRD2HTR2A | |
| SCHEMBL3950179 | 0.83 | DRD2 (0.35) | CYP1A2ALDH1A1KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL8233850 | 0.82 | ALDH1A1 (0.46) | CYP1A2ALDH1A1KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL3947071 | 0.82 | DRD2 (0.34) | CYP1A2ALDH1A1KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL3957451 | 0.82 | ALDH1A1 (0.35) | CYP1A2ALDH1A1KDM4EDRD2HTR2A | |
| SCHEMBL3947832 | 0.82 | DRD2 (0.34) | ALDH1A1DRD2HTR2ADRD3 | |
| SCHEMBL3947017 | 0.82 | RAD52 (0.40) | ALDH1A1SMN1; SMN2DRD2HTR2ADRD3 | |
| SCHEMBL12120559 | 0.82 | ALOX15 (0.50) | ALDH1A1KEAP1SMN1; SMN2KDM4EDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | CYP1A2 1663/4885HRH3 571/4885ALDH1A1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.